Identification of human presequence protease (hPreP) agonists for the treatment of Alzheimer's disease.
Ontology highlight
ABSTRACT: Amyloid-β (Aβ), a neurotoxic peptide, is linked to the onset of Alzheimer's disease (AD). Increased Aβ content within neuronal cell mitochondria is a pathological feature in both human and mouse models with AD. This accumulation of Aβ within the mitochondrial landscape perpetuates increased free radical production and activation of the apoptotic pathway. Human Presequence Protease (hPreP) is responsible for the degradation of mitochondrial amyloid-β peptide in human neuronal cells, and is thus an attractive target to increase the proteolysis of Aβ. Therefore, it offers a potential target for Alzheimer's drug design, by identifying potential activators of hPreP. We applied structure-based drug design, combined with experimental methodologies to investigate the ability of various compounds t
SUBMITTER: Vangavaragu JR
PROVIDER: S-EPMC4381964 | biostudies-literature | 2014 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA